Literature DB >> 20209307

The role of the FEF50%/0.5FVC ratio in the diagnosis of obstructive lung diseases.

Marcelo Tadday Rodrigues1, Daniel Fiterman-Molinari, Sérgio Saldanha Menna Barreto, Jussara Fiterman.   

Abstract

OBJECTIVE: To evaluate the contribution of a new coefficient, the FEF50%/0.5FVC ratio, obtained from the maximal expiratory flow-volume curve, to the diagnosis of obstructive lung disease (OLD); to test this coefficient in differentiating among patients considered normal, those with OLD and those with restrictive lung disease (RLD); and to determine cut-off points for each functional diagnosis, as well as the probability for each diagnosis based on individual values.
METHODS: A prospective, cross-sectional study analyzing the pulmonary function of patients referred to the Porto Alegre Hospital de Clínicas, in Porto Alegre, Brazil, between January and December of 2003. We collected demographic and spirometric data. The patients were divided into three groups: normal; OLD; and RLD. We calculated the FEV1/FVC and FEF50%/0.5FVC ratios, and we compared the mean FEF50%/0.5FVC values among the groups. We used Pearson's correlation test in order to compare FEF50%/0.5FVC with FEV1/FVC. The patients were again divided into two groups: those with OLD and those without OLD. We calculated the likelihood ratio for different cut-off points.
RESULTS: The mean age of the patients was 55.8 +/- 14.7 years. There were significant differences among the groups in terms of the mean FEF50%/0.5FVC (2.10 +/- 0.82, 2.55 +/- 1.47 and 0.56 +/- 0.29, respectively, for normal, RLD and OLD; p < 0.001). There was a positive correlation between FEF50%/0.5FVC and FEV1/FVC in the OLD group (r = 0.83). We found that an FEF50%/0.5FVC < 0.79 strongly suggests OLD, whereas an FEF50%/0.5FVC > 1.33 practically excludes this diagnosis.
CONCLUSIONS: The FEF50%/0.5FVC ratio is a potentially useful parameter in the differential diagnosis of OLD and correlates positively with the FEV1/FVC ratio.

Entities:  

Mesh:

Year:  2010        PMID: 20209307     DOI: 10.1590/s1806-37132010000100009

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  5 in total

1.  HIV infection model of chronic obstructive pulmonary disease in mice.

Authors:  Patrick Geraghty; Eran Hadas; Boe-Hyun Kim; Abdoulaye J Dabo; David J Volsky; Robert Foronjy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-19       Impact factor: 5.464

Review 2.  Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC.

Authors:  Daniel Hoesterey; Nilakash Das; Wim Janssens; Russell G Buhr; Fernando J Martinez; Christopher B Cooper; Donald P Tashkin; Igor Barjaktarevic
Journal:  Respir Med       Date:  2019-08-09       Impact factor: 3.415

Review 3.  A survey of recently published cardiovascular, hematological and pneumological original articles in the Brazilian scientific press.

Authors:  Kavita Kirankumar Patel; Bruno Caramelli; Ariane Gomes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 4.  Airway disease: similarities and differences between asthma, COPD and bronchiectasis.

Authors:  Rodrigo Athanazio
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

5.  Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control.

Authors:  Jianghong Wei; Libing Ma; Jiying Wang; Qing Xu; Meixi Chen; Ming Jiang; Miao Luo; Jingjie Wu; Weiwei She; Shuyuan Chu; Biwen Mo
Journal:  Allergy Asthma Clin Immunol       Date:  2018-12-27       Impact factor: 3.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.